473 related articles for article (PubMed ID: 23876235)
1. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
[TBL] [Abstract][Full Text] [Related]
2. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.
Dua R; Zhang J; Nhonthachit P; Penuel E; Petropoulos C; Parry G
Breast Cancer Res Treat; 2010 Aug; 122(3):685-97. PubMed ID: 19859802
[TBL] [Abstract][Full Text] [Related]
3. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
[TBL] [Abstract][Full Text] [Related]
4. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G
J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222
[TBL] [Abstract][Full Text] [Related]
5. Carcinoembryonic antigen cell adhesion molecule 6 predicts breast cancer recurrence following adjuvant tamoxifen.
Maraqa L; Cummings M; Peter MB; Shaaban AM; Horgan K; Hanby AM; Speirs V
Clin Cancer Res; 2008 Jan; 14(2):405-11. PubMed ID: 18223215
[TBL] [Abstract][Full Text] [Related]
6. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells.
Aesoy R; Sanchez BC; Norum JH; Lewensohn R; Viktorsson K; Linderholm B
Mol Cancer Res; 2008 Oct; 6(10):1630-8. PubMed ID: 18922978
[TBL] [Abstract][Full Text] [Related]
7. ABCC11 expression is regulated by estrogen in MCF7 cells, correlated with estrogen receptor alpha expression in postmenopausal breast tumors and overexpressed in tamoxifen-resistant breast cancer cells.
Honorat M; Mesnier A; Vendrell J; Guitton J; Bieche I; Lidereau R; Kruh GD; Dumontet C; Cohen P; Payen L
Endocr Relat Cancer; 2008 Mar; 15(1):125-38. PubMed ID: 18310281
[TBL] [Abstract][Full Text] [Related]
8. Trefoil factor 3 is oncogenic and mediates anti-estrogen resistance in human mammary carcinoma.
Kannan N; Kang J; Kong X; Tang J; Perry JK; Mohankumar KM; Miller LD; Liu ET; Mertani HC; Zhu T; Grandison PM; Liu DX; Lobie PE
Neoplasia; 2010 Dec; 12(12):1041-53. PubMed ID: 21170268
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.
Hochgräfe F; Zhang L; O'Toole SA; Browne BC; Pinese M; Porta Cubas A; Lehrbach GM; Croucher DR; Rickwood D; Boulghourjian A; Shearer R; Nair R; Swarbrick A; Faratian D; Mullen P; Harrison DJ; Biankin AV; Sutherland RL; Raftery MJ; Daly RJ
Cancer Res; 2010 Nov; 70(22):9391-401. PubMed ID: 20861192
[TBL] [Abstract][Full Text] [Related]
10. Differential regulation of ErbB2 expression by cAMP-dependent protein kinase in tamoxifen-resistant breast cancer cells.
Yang JW; Kim MR; Kim HG; Kim SK; Jeong HG; Kang KW
Arch Pharm Res; 2008 Mar; 31(3):350-6. PubMed ID: 18409049
[TBL] [Abstract][Full Text] [Related]
11. Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumour-stroma interactions.
Hiscox S; Jordan NJ; Jiang W; Harper M; McClelland R; Smith C; Nicholson RI
Endocr Relat Cancer; 2006 Dec; 13(4):1085-99. PubMed ID: 17158755
[TBL] [Abstract][Full Text] [Related]
12. A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer.
Rokavec M; Schroth W; Amaral SM; Fritz P; Antoniadou L; Glavac D; Simon W; Schwab M; Eichelbaum M; Brauch H
Cancer Res; 2008 Dec; 68(23):9799-808. PubMed ID: 19047159
[TBL] [Abstract][Full Text] [Related]
13. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
14. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
Chang SB; Miron P; Miron A; Iglehart JD
J Surg Res; 2007 Mar; 138(1):37-44. PubMed ID: 17109887
[TBL] [Abstract][Full Text] [Related]
15. Post-transcriptional regulation of ERBB2 by miR26a/b and HuR confers resistance to tamoxifen in estrogen receptor-positive breast cancer cells.
Tan S; Ding K; Chong QY; Zhao J; Liu Y; Shao Y; Zhang Y; Yu Q; Xiong Z; Zhang W; Zhang M; Li G; Li X; Kong X; Ahmad A; Wu Z; Wu Q; Zhao X; Lobie PE; Zhu T
J Biol Chem; 2017 Aug; 292(33):13551-13564. PubMed ID: 28637868
[TBL] [Abstract][Full Text] [Related]
16. Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer.
Lanigan F; McKiernan E; Brennan DJ; Hegarty S; Millikan RC; McBryan J; Jirstrom K; Landberg G; Martin F; Duffy MJ; Gallagher WM
Int J Cancer; 2009 May; 124(9):2088-97. PubMed ID: 19142967
[TBL] [Abstract][Full Text] [Related]
17. Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression.
Giordano C; Catalano S; Panza S; Vizza D; Barone I; Bonofiglio D; Gelsomino L; Rizza P; Fuqua SA; Andò S
Oncogene; 2011 Sep; 30(39):4129-40. PubMed ID: 21499302
[TBL] [Abstract][Full Text] [Related]
18. Integrative analysis of miRNA and gene expression reveals regulatory networks in tamoxifen-resistant breast cancer.
Joshi T; Elias D; Stenvang J; Alves CL; Teng F; Lyng MB; Lykkesfeldt AE; Brünner N; Wang J; Gupta R; Workman CT; Ditzel HJ
Oncotarget; 2016 Aug; 7(35):57239-57253. PubMed ID: 27528030
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of FGFR3 actions in endocrine resistant breast cancer.
Tomlinson DC; Knowles MA; Speirs V
Int J Cancer; 2012 Jun; 130(12):2857-66. PubMed ID: 21792889
[TBL] [Abstract][Full Text] [Related]
20. Nudix-type motif 2 in human breast carcinoma: a potent prognostic factor associated with cell proliferation.
Oka K; Suzuki T; Onodera Y; Miki Y; Takagi K; Nagasaki S; Akahira J; Ishida T; Watanabe M; Hirakawa H; Ohuchi N; Sasano H
Int J Cancer; 2011 Apr; 128(8):1770-82. PubMed ID: 20533549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]